{"id":714451,"date":"2022-11-22T16:39:46","date_gmt":"2022-11-22T21:39:46","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/akebia-therapeutics-to-participate-in-the-piper-sandler-34th-annual-healthcare-conference\/"},"modified":"2022-11-22T16:39:46","modified_gmt":"2022-11-22T21:39:46","slug":"akebia-therapeutics-to-participate-in-the-piper-sandler-34th-annual-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/akebia-therapeutics-to-participate-in-the-piper-sandler-34th-annual-healthcare-conference\/","title":{"rendered":"Akebia Therapeutics to Participate in the Piper Sandler 34th Annual Healthcare Conference"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"legendSpanClass\"><br \/>\n          <span class=\"xn-location\">CAMBRIDGE, Mass.<\/span><br \/>\n        <\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">Nov. 22, 2022<\/span><\/span> \/PRNewswire\/ &#8212; <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3717129-1&amp;h=3912083839&amp;u=http%3A%2F%2Fwww.akebia.com%2F&amp;a=Akebia+Therapeutics%2C+Inc.\" target=\"_blank\" rel=\"nofollow noopener\">Akebia Therapeutics, Inc.<\/a>\u00a0(Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the company will participate in the Piper Sandler 34<sup>th<\/sup> Annual Healthcare Conference, which takes place <span class=\"xn-chron\">November 29-December 1, 2022<\/span> in New York City,\u00a0New York.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/1136400\/Akebia_Logo.html\" target=\"_blank\" rel=\"nofollow noopener\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/1136400\/Akebia_Logo.jpg\" title=\"Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease (PRNewsfoto\/Akebia Therapeutics, Inc.)\" alt=\"Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease (PRNewsfoto\/Akebia Therapeutics, Inc.)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p>\n        <span class=\"xn-person\">John P. Butler<\/span>, Chief Executive Officer of Akebia Therapeutics, will participate in a fireside chat on <span class=\"xn-chron\">Tuesday, November 29<\/span> at <span class=\"xn-chron\">2:30 p.m. ET<\/span>.<\/p>\n<p>A webcast of the fireside chat will be available through the Investors section of Akebia&#8217;s website at <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3717129-1&amp;h=1322999563&amp;u=https%3A%2F%2Fir.akebia.com%2F&amp;a=https%3A%2F%2Fir.akebia.com\" target=\"_blank\" rel=\"nofollow noopener\">https:\/\/ir.akebia.com<\/a>\u00a0for approximately 90 days following the conference.<\/p>\n<p>\n        <b>About Akebia Therapeutics\u00a0<br \/><\/b>Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in <span class=\"xn-location\">Cambridge, Massachusetts<\/span>. For more information, please visit our website at <a href=\"http:\/\/www.akebia.com\" rel=\"nofollow\">www.akebia.com<\/a>, which does not form a part of this release.<\/p>\n<p>\n        <b>Akebia Therapeutics Contact\u00a0<br \/><\/b>Mercedes Carrasco\u00a0<br \/><a href=\"mailto:Mcarrasco@akebia.com\" target=\"_blank\" rel=\"nofollow noopener\">Mcarrasco@akebia.com<\/a>\u00a0<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder2\"><\/div>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=NE44503&amp;sd=2022-11-22\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow noopener\" href=\"https:\/\/www.prnewswire.com\/news-releases\/akebia-therapeutics-to-participate-in-the-piper-sandler-34th-annual-healthcare-conference-301685166.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/akebia-therapeutics-to-participate-in-the-piper-sandler-34th-annual-healthcare-conference-301685166.html<\/a><\/p>\n<p>SOURCE  Akebia Therapeutics<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=NE44503&amp;Transmission_Id=202211221605PR_NEWS_USPR_____NE44503&amp;DateId=20221122\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire CAMBRIDGE, Mass. , Nov. 22, 2022 \/PRNewswire\/ &#8212; Akebia Therapeutics, Inc.\u00a0(Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the company will participate in the Piper Sandler 34th Annual Healthcare Conference, which takes place November 29-December 1, 2022 in New York City,\u00a0New York. John P. Butler, Chief Executive Officer of Akebia Therapeutics, will participate in a fireside chat on Tuesday, November 29 at 2:30 p.m. ET. A webcast of the fireside chat will be available through the Investors section of Akebia&#8217;s website at https:\/\/ir.akebia.com\u00a0for approximately 90 days following the conference. About Akebia Therapeutics\u00a0Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/akebia-therapeutics-to-participate-in-the-piper-sandler-34th-annual-healthcare-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Akebia Therapeutics to Participate in the Piper Sandler 34th Annual Healthcare Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-714451","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Akebia Therapeutics to Participate in the Piper Sandler 34th Annual Healthcare Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/akebia-therapeutics-to-participate-in-the-piper-sandler-34th-annual-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Akebia Therapeutics to Participate in the Piper Sandler 34th Annual Healthcare Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire CAMBRIDGE, Mass. , Nov. 22, 2022 \/PRNewswire\/ &#8212; Akebia Therapeutics, Inc.\u00a0(Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the company will participate in the Piper Sandler 34th Annual Healthcare Conference, which takes place November 29-December 1, 2022 in New York City,\u00a0New York. John P. Butler, Chief Executive Officer of Akebia Therapeutics, will participate in a fireside chat on Tuesday, November 29 at 2:30 p.m. ET. A webcast of the fireside chat will be available through the Investors section of Akebia&#8217;s website at https:\/\/ir.akebia.com\u00a0for approximately 90 days following the conference. About Akebia Therapeutics\u00a0Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better &hellip; Continue reading &quot;Akebia Therapeutics to Participate in the Piper Sandler 34th Annual Healthcare Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/akebia-therapeutics-to-participate-in-the-piper-sandler-34th-annual-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-22T21:39:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/1136400\/Akebia_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akebia-therapeutics-to-participate-in-the-piper-sandler-34th-annual-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akebia-therapeutics-to-participate-in-the-piper-sandler-34th-annual-healthcare-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Akebia Therapeutics to Participate in the Piper Sandler 34th Annual Healthcare Conference\",\"datePublished\":\"2022-11-22T21:39:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akebia-therapeutics-to-participate-in-the-piper-sandler-34th-annual-healthcare-conference\\\/\"},\"wordCount\":195,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akebia-therapeutics-to-participate-in-the-piper-sandler-34th-annual-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1136400\\\/Akebia_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akebia-therapeutics-to-participate-in-the-piper-sandler-34th-annual-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akebia-therapeutics-to-participate-in-the-piper-sandler-34th-annual-healthcare-conference\\\/\",\"name\":\"Akebia Therapeutics to Participate in the Piper Sandler 34th Annual Healthcare Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akebia-therapeutics-to-participate-in-the-piper-sandler-34th-annual-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akebia-therapeutics-to-participate-in-the-piper-sandler-34th-annual-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1136400\\\/Akebia_Logo.jpg\",\"datePublished\":\"2022-11-22T21:39:46+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akebia-therapeutics-to-participate-in-the-piper-sandler-34th-annual-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akebia-therapeutics-to-participate-in-the-piper-sandler-34th-annual-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akebia-therapeutics-to-participate-in-the-piper-sandler-34th-annual-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1136400\\\/Akebia_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1136400\\\/Akebia_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/akebia-therapeutics-to-participate-in-the-piper-sandler-34th-annual-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Akebia Therapeutics to Participate in the Piper Sandler 34th Annual Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Akebia Therapeutics to Participate in the Piper Sandler 34th Annual Healthcare Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/akebia-therapeutics-to-participate-in-the-piper-sandler-34th-annual-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"Akebia Therapeutics to Participate in the Piper Sandler 34th Annual Healthcare Conference - Market Newsdesk","og_description":"PR Newswire CAMBRIDGE, Mass. , Nov. 22, 2022 \/PRNewswire\/ &#8212; Akebia Therapeutics, Inc.\u00a0(Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the company will participate in the Piper Sandler 34th Annual Healthcare Conference, which takes place November 29-December 1, 2022 in New York City,\u00a0New York. John P. Butler, Chief Executive Officer of Akebia Therapeutics, will participate in a fireside chat on Tuesday, November 29 at 2:30 p.m. ET. A webcast of the fireside chat will be available through the Investors section of Akebia&#8217;s website at https:\/\/ir.akebia.com\u00a0for approximately 90 days following the conference. About Akebia Therapeutics\u00a0Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better &hellip; Continue reading \"Akebia Therapeutics to Participate in the Piper Sandler 34th Annual Healthcare Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/akebia-therapeutics-to-participate-in-the-piper-sandler-34th-annual-healthcare-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2022-11-22T21:39:46+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/1136400\/Akebia_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akebia-therapeutics-to-participate-in-the-piper-sandler-34th-annual-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akebia-therapeutics-to-participate-in-the-piper-sandler-34th-annual-healthcare-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Akebia Therapeutics to Participate in the Piper Sandler 34th Annual Healthcare Conference","datePublished":"2022-11-22T21:39:46+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akebia-therapeutics-to-participate-in-the-piper-sandler-34th-annual-healthcare-conference\/"},"wordCount":195,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akebia-therapeutics-to-participate-in-the-piper-sandler-34th-annual-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1136400\/Akebia_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akebia-therapeutics-to-participate-in-the-piper-sandler-34th-annual-healthcare-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/akebia-therapeutics-to-participate-in-the-piper-sandler-34th-annual-healthcare-conference\/","name":"Akebia Therapeutics to Participate in the Piper Sandler 34th Annual Healthcare Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akebia-therapeutics-to-participate-in-the-piper-sandler-34th-annual-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akebia-therapeutics-to-participate-in-the-piper-sandler-34th-annual-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1136400\/Akebia_Logo.jpg","datePublished":"2022-11-22T21:39:46+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akebia-therapeutics-to-participate-in-the-piper-sandler-34th-annual-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/akebia-therapeutics-to-participate-in-the-piper-sandler-34th-annual-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akebia-therapeutics-to-participate-in-the-piper-sandler-34th-annual-healthcare-conference\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/1136400\/Akebia_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/1136400\/Akebia_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/akebia-therapeutics-to-participate-in-the-piper-sandler-34th-annual-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Akebia Therapeutics to Participate in the Piper Sandler 34th Annual Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/714451","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=714451"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/714451\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=714451"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=714451"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=714451"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}